Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43

European Journal of Pharmacology

Volumn 466, Issue 1-2, 2003, Pages 7-12

  Krusekopf, Solveigh ^a,c   Roots, Ivar ^a   Kleeberg, Ullrich ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Fed Inst for Drugs/Med Devices   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CYP3A (Cytochrome P450 3A); Induction of transcription; Omeprazole; Pantoprazole; RT PCR (reverse transcription polymerase chain reaction); St. John's wort

Indexed keywords

ARISTON; BENZIMIDAZOLE DERIVATIVE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A43; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DACTINOMYCIN; DEXAMETHASONE; HYPERICUM PERFORATUM EXTRACT; ISOENZYME; LANSOPRAZOLE; MESSENGER RNA; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 0037432689     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01481-X     Document Type: Article

References (30)

1. Bertilsson G., Berkenstam A., Blomquist P. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun. 280:2001;139-144.
2. Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J.C., Clair P., Gervot L., Lesca P., Domergue J., Joyeux H., Fourtanier G. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269:1994;384-392.
3. Domanski T.L., Finta C., Halpert J.R., Zaphiropoulos P.G. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59:2001;386-392.
4. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., Deglmann C.J., Burk O., Buntefuss D., Escher S., Bishop C., Koebe H.G., Brinkmann U., Klenk H.P., Kleine K., Meyer U.A., Wojnowski L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 11:2001;111-121.
5. Gibbs M.A., Thummel K.E., Shen D.D., Kunze K.L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 27:1999;180-187.
6. Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56:1999;1329-1339.
7. Haehner B.D., Gorski J.C., Vandenbranden M., Wrighton S.A., Janardan S.K., Watkins P.B., Hall S.D. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol. 50:1996;52-59.
8. Iwano S., Saito T., Takahashi Y., Fujita K., Kamataki T. Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members. Biochem. Biophys. Res. Commun. 286:2001;55-60.
9. Krusekopf S., Kleeberg U., Hildebrandt A.G., Ruckpaul K. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. Xenobiotica. 27:1997;1-9.
10. +-ATPase inhibitors and other xenobiotics. Xenobiotica. 33:2003;. (in press, DOI 10.1080/0049825021000023978).
11. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M.S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:2001;383-391.
12. LeCluyse E.L. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem. Biol. Interact. 16:2001;283-289. (Review).
13. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1998;1016-1023.
14. Masubuchi N., Li A.P., Okazaki O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem. Biol. Interact. 114:1998;1-13.
15. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A. 97:2000;7500-7502.
16. Ogg M.S., Williams J.M., Tarbit M., Goldfarb P.S., Gray T.J., Gibson G.G. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica. 29:1999;269-279.
17. Ohmori S., Nakasa H., Asanome K., Kurose Y., Ishii I., Hosokawa M., Kitada M. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta. 1380:1998;297-304.
18. Pascussi J.M., Jounaidi Y., Drocourt L., Domergue J., Balabaud C., Maurel P., Vilarem M.J. Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun. 260:1999;377-381.
19. Pascussi J.M., Drocourt L., Gerbal-Chaloin S., Fabre J.M., Maurel P., Vilarem M.J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem. 268:2001;6346-6358.
20. Rodriguez-Antona C., Donato M.T., Pareja E., Gomez-Lechon M.J., Castell J.V. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch. Biochem. Biophys. 393:2001;308-315.
21. Saito T., Takahashi Y., Hashimoto H., Kamataki T. Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. J. Biol. Chem. 276:2001;38010-38022.
22. Schuetz J.D., Beach D.L., Guzelian P.S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics. 4:1994;11-20.
23. Schuetz J.D., Schuetz E.G., Thottassery J.V., Guzelian P.S., Strom S., Sun D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol. 49:1996;63-72.
24. Sumida A., Kinoshita K., Fukuda T., Matsuda H., Yamamoto I., Inaba T., Azuma J. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem. Biophys. Res. Commun. 262:1999;499-503.
25. Sumida A., Yamamoto I., Zhou Q., Morisaki T., Azuma J. Evaluation of induction of CYP3A mRNA using the HepG2 cell line and reverse transcription-PCR. Biol. Pharm. Bull. 22:1999;61-65.
26. Sy S.K., Ciaccia A., Li W., Roberts E.A., Okey A., Kalow W., Tang B.K. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur. J. Clin. Pharmacol. 58:2002;357-365.
27. Thummel K.E., Wilkinson G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38:1998;389-430.
28. Westlind A., Malmebo S., Johansson I., Otter C., Andersson T.B., Ingelman-Sundberg M., Oscarson M. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 281:2001;1349-1355.
29. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., Hamman M.A., Hall S.D., Wrighton S.A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30:2002;883-891.
30. Wrighton S.A., Brian W.R., Sari M.A., Iwasaki M., Guengerich F.P., Raucy J.L., Molowa D.T., Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38:1990;207-213.